Biocardia Inc (BCDA)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$0.94

+0.01 (+1.22%)

Market Cap: $14.99M

Last updated: Oct 16, 2026 at 1:54 PM ET

Earnings

Performance (10Y)

Beat Rate

68%(19/28)

Avg Surprise

-14.03%

Streak

1 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.15

Range$-0.15 - $-0.15

1 analysts

EPS Revisions

30d

EPS Estimate DriftChange to current

90d ago$-0.17+11.8%

60d ago$-0.18+16.7%

30d ago$-0.18+16.7%

7d ago$-0.18+16.7%

Current$-0.15

Revenue Consensus

Range$0 - $0

2 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.20

Range$-0.20 - $-0.20

1 analysts

Revenue Consensus

Range$0 - $0

2 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.20	$-0.20 - $-0.20	-	-	1	-	-
Sep 30, 2026Sep 26EST	-	$-0.15	$-0.15 - $-0.15	-	-	1	1 0 30d	-
Jun 30, 2026Jun 26 Reported Aug 12, 2026Reported Aug 12	$-0.13	$-0.19	$-0.19 - $-0.19	+31.58%	Beat	1	0 1 30d	+67.5%
Mar 31, 2026Mar 26 Reported May 15, 2026Reported May 15	$-0.21	$-0.17	$-0.17 - $-0.17	-23.53%	Miss	1	No revisions (30d)	+64.4%
Dec 31, 2025Dec 25 Reported Mar 24, 2026Reported Mar 24	$-0.06	N/A	-	+70.00%	Beat	1	1 0 30d	+76.0%
Sep 30, 2025Sep 25 Reported Nov 12, 2025Reported Nov 12	$-0.24	$-0.25	$-0.25 - $-0.25	+4.00%	Beat	1	No revisions (30d)	+60.7%
Jun 30, 2025Jun 25 Reported Aug 11, 2025Reported Aug 11	$-0.40	$-0.50	$-0.50 - $-0.50	+20.00%	Beat	0	No revisions (30d)	+54.5%
Mar 31, 2025Mar 25 Reported May 14, 2025Reported May 14	$-0.59	$-0.39	$-0.39 - $-0.39	-51.28%	Miss	0	No revisions (30d)	-554.1%
Dec 31, 2024Dec 24 Reported Mar 26, 2025Reported Mar 26	$-0.25	N/A	-	+71.26%	Beat	1	1 0 30d	+81.5%
Sep 30, 2024Sep 24 Reported Nov 13, 2024Reported Nov 13	$-0.61	$-1.19	-	+48.74%	Beat	-	-	+66.1%
Jun 30, 2024Jun 24 Reported Aug 13, 2024Reported Aug 13	$-0.88	$-0.10	$-0.10 - $-0.10	-780.00%	Miss	0	No revisions (30d)	+65.5%
Mar 31, 2024Mar 24 Reported May 14, 2024Reported May 14	$-0.09	N/A	-	+54.90%	Beat	0	No revisions (30d)	+96.5%
Dec 31, 2023Dec 23 Reported Mar 27, 2024Reported Mar 27	$-1.35	$-1.50	$-1.51 - $-1.49	+10.00%	Beat	2	No revisions (30d)	-743.8%
Sep 30, 2023Sep 23 Reported Nov 8, 2023Reported Nov 8	$-1.80	$-1.65	$-1.66 - $-1.64	-9.09%	Miss	2	No revisions (30d)	+29.4%
Jun 30, 2023Jun 23 Reported Aug 9, 2023Reported Aug 9	$-2.55	$-2.55	$-2.56 - $-2.52	+0.00%	Beat	3	0 1 30d	-21.4%
Mar 31, 2023Mar 23 Reported May 10, 2023Reported May 10	$-2.55	$-1.95	$-2.01 - $-1.92	-30.77%	Miss	3	No revisions (30d)	+10.5%
Dec 31, 2022Dec 22 Reported Mar 29, 2023Reported Mar 29	$-0.16	$-0.18	$-0.22 - $-0.13	+11.11%	Beat	3	No revisions (30d)	+20.0%
Sep 30, 2022Sep 22 Reported Nov 9, 2022Reported Nov 9	$-2.55	$-3.15	$-3.17 - $-3.13	+19.05%	Beat	4	No revisions (30d)	-6.2%
Jun 30, 2022Jun 22 Reported Aug 10, 2022Reported Aug 10	$-2.10	N/A	-	+66.67%	Beat	5	No revisions (30d)	+30.0%
Mar 31, 2022Mar 22 Reported May 11, 2022Reported May 11	$-2.85	$-2.40	$-2.49 - $-2.33	-18.75%	Miss	3	No revisions (30d)	-1483.3%
Dec 31, 2021Dec 21 Reported Mar 29, 2022Reported Mar 29	$-0.20	$-0.21	$-0.25 - $-0.12	+4.76%	Beat	4	No revisions (30d)	+93.4%
Sep 30, 2021Sep 21 Reported Nov 10, 2021Reported Nov 10	$-2.40	$-4.20	$-4.26 - $-4.17	+42.86%	Beat	4	No revisions (30d)	+46.7%
Jun 30, 2021Jun 21 Reported Aug 12, 2021Reported Aug 12	$-3.00	$-3.45	$-3.48 - $-3.43	+13.04%	Beat	3	No revisions (30d)	+56.5%
Mar 31, 2021Mar 21 Reported May 13, 2021Reported May 13	$-0.18	$-0.24	$-0.28 - $-0.21	+25.00%	Beat	2	1 0 30d	+97.5%
Dec 31, 2020Dec 20 Reported Mar 30, 2021Reported Mar 30	$-3.05	$-4.65	$-4.66 - $-4.63	+34.41%	Beat	3	No revisions (30d)	-535.4%
Sep 30, 2020Sep 20 Reported Nov 10, 2020Reported Nov 10	$-4.50	$-4.35	$-4.36 - $-4.34	-3.45%	Miss	4	No revisions (30d)	+52.4%
Jun 30, 2020Jun 20 Reported Aug 13, 2020Reported Aug 13	$-6.90	$-6.00	$-6.00 - $-6.00	-15.00%	Miss	0	No revisions (30d)	-796.1%
Mar 31, 2020Mar 20 Reported Apr 9, 2020Reported Apr 9	$-7.20	$-8.40	$-8.40 - $-8.40	+14.29%	Beat	1	No revisions (30d)	-747.1%
Dec 31, 2019Dec 19 Reported Dec 31, 2019Reported Dec 31	$-0.48	$-0.51	$-0.56 - $-0.46	+5.88%	Beat	2	No revisions (30d)	+43.3%
Sep 30, 2019Sep 19 Reported Nov 19, 2019Reported Nov 19	$-9.45	$-8.70	-	-8.62%	Miss	-	-	-1066.7%
Jun 30, 2019Jun 19 Reported Aug 21, 2019Reported Aug 21	$-0.77	N/A	-	N/A	Beat	-	-	-6.9%
Mar 31, 2019Mar 19 Reported Apr 2, 2019Reported Apr 2	$-0.85	N/A	-	N/A	Beat	-	-	+88.8%
Dec 31, 2018Dec 18 Reported Mar 22, 2019Reported Mar 22	$-0.85	N/A	-	N/A	Beat	-	-	-4.5%
Sep 30, 2018Sep 18 Reported Nov 8, 2018Reported Nov 8	$-0.81	N/A	-	N/A	Beat	-	-	-12.5%
Jun 30, 2018Jun 18 Reported Aug 9, 2018Reported Aug 9	$-0.72	N/A	-	N/A	Beat	-	-	+93.1%
Mar 31, 2018Mar 18 Reported May 10, 2018Reported May 10	$-7.59	N/A	-	N/A	Beat	-	-	+25.4%
Dec 31, 2017Dec 17 Reported Mar 16, 2018Reported Mar 16	$-0.81	N/A	-	N/A	Beat	-	-	-
Sep 30, 2017Sep 17 Reported Nov 9, 2017Reported Nov 9	$-0.72	N/A	-	N/A	Beat	-	-	-
Jun 30, 2017Jun 17 Reported Aug 14, 2017Reported Aug 14	$-10.42	N/A	-	N/A	Beat	-	-	-
Mar 31, 2017Mar 17 Reported May 11, 2017Reported May 11	$-10.18	N/A	-	N/A	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	-1.47	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	0.00%
ROE	-1803.00%	ROIC	N/A
Financial Health
Debt/Equity	0.00x	Interest Coverage	N/A
Current Ratio	2.09x	Quick Ratio	2.09x
Trading Statistics
Beta	0.62	Avg Volume	312.50K
52-Week High	$1.52	52-Week Low	$0.75

Technical Indicators Dashboard

Moving Averages

SMA 10$1.03

SMA 20$1.04

SMA 50$1.05

SMA 200$1.10

EMA 10$1.01

EMA 20$1.03

EMA 50$1.04

EMA 200$1.14

MACD

Line: -0.03Signal: -0.01Hist: -0.02

ADX

ADX: 17.6+DI: 13.3-DI: 27.3

Aroon & PSAR

Aroon Up16.0

Aroon Down100.0

PSAR$1.10

Bollinger Bands

Upper Band$1.15

Lower Band$0.94

%B Position2024%(Upper)

Band Width0.01

RSI (14-Day)

Neutral

37.3

Momentum Oscillators

Stoch %K15.0

Stoch %D18.4

Williams %R-71.8

ROC (10d)-8.0%

Momentum-0.08

CCI (20d)-223.5

MFI (14d)11.3

Volatility Measures

ATR (14d)$0.07(7.4%)

StdDev (20d)0.05

Hist Vol52.2%(High)

Volume Flow

VWAP$0.93

OBV130.6M

AD Line-125.8M

CMF (20d)-0.301

Volume Metrics

Avg Vol (20d)246.4K

Vol Ratio1.0x

VWMA (20d)$1.06

Pivot Points

R3$1.07

R2$1.04

R1$0.98

Pivot Point$0.95

S1$0.89

S2$0.85

S3$0.80

Advanced Oscillators

TSI-11.48

Ultimate Osc45.4

KST-56.23

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$0	$0	$0	$0	$0	$0	$-55,000	$0	$0	$55,000	$13,000	$357,000
Cost of Revenue	$0	$0	$185,000	$0	$0	$0	$1.42M	$0	$0	$0	$1.16M	$0
Gross Profit	$0	$0	$-185,000	$0	$0	$0	$-55,000	$0	$0	$55,000	$13,000	$357,000

Operating Expenses	$1.62M	$2.27M	$2.01M	$1.49M	$2.05M	$2.73M	$2.32M	$1.76M	$1.65M	$2.33M	$2.10M	$2.96M
R&D	$893,000	$1.24M	$1.13M	$936,000	$1.37M	$1.53M	$1.42M	$931,000	$800,000	$1.24M	$1.16M	$1.87M
SG&A	$730,000	$1.03M	$885,000	$552,000	$683,000	$1.20M	$906,000	$825,000	$852,000	$1.09M	$941,000	$1.08M
Operating Income	$-1,623,000	$-2,266,000	$-2,013,000	$-1,488,000	$-2,051,000	$-2,726,000	$-2,321,000	$-1,756,000	$-1,649,000	$-2,275,000	$-2,084,000	$-2,598,000

Interest Income	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Interest Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$28,000	$0
Income Before Tax	$-1,613,000	$-2,259,000	$-1,984,000	$-1,483,000	$-2,049,000	$-2,712,000	$-2,288,000	$-1,737,000	$-1,646,000	$-2,275,000	$-2,112,000	$-2,598,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-1,613,000	$-2,259,000	$-1,984,000	$-1,483,000	$-2,049,000	$-2,712,000	$-2,296,000	$-1,737,000	$-1,646,000	$-2,267,000	$-2,072,000	$-2,574,000

EBITDA	$-1,499,000	$-2,142,000	$-1,828,000	$-1,381,000	$-1,928,000	$-2,593,000	$-2,092,000	$-1,648,000	$-1,543,000	$-2,169,000	$-2,064,000	$-2,577,000
EBIT	$-1,623,000	$-2,266,000	$-2,013,000	$-1,488,000	$-2,051,000	$-2,726,000	$-2,321,000	$-1,756,000	$-1,649,000	$-2,275,000	$-2,084,000	$-2,598,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about BCDA

News

FDA agrees BioCardia's heart-failure trial may support approval of its cell treatment.

BioCardia (BCDA) is presenting the design of its CardiAMP HF II trial at the HFSA Annual Scientific Meeting, a study focused on high-dose cell treatment for ischemic heart failure. The FDA has indicated that this ongoing...

Stock Titan•Oct 8, 2026 8:40 AM ET10/8/26•Neutral

BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting

BioCardia, Inc. is set to present the design and scientific support for its CardiAMP HF II Study at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026. The study aims to evaluate the efficacy...

The Manila Times•Oct 7, 2026 8:55 AM ET10/7/26•Somewhat-Bullish

BioCardia, Inc. (BCDA) Stock Price, News, Quote & History

This article provides detailed financial information, news, and historical data for BioCardia, Inc. (BCDA), a clinical-stage regenerative medicine company focusing on cardiovascular and pulmonary diseases. It includes...

Yahoo! Finance Canada•Oct 2, 2026 10:24 AM ET10/2/26•Neutral

FDA targets an initial review within 15 calendar days for a device that delivers therapy to the heart.

BioCardia (BCDA) has submitted a revised De Novo pre-submission to the FDA for its Helix catheter, which delivers therapeutic and diagnostic agents to the heart. The FDA has indicated it will provide an initial...

Stock Titan•Oct 1, 2026 8:01 PM ET10/1/26•Bullish

BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter

BioCardia, Inc. has submitted a revised De Novo pre-submission to the FDA for its Helix™ Catheter, designed for therapeutic and diagnostic agent delivery to the heart. This submission follows a meeting with the FDA...

GlobeNewswire•Oct 1, 2026 8:01 PM ET10/1/26•Bullish

BCDA Valuation and Fair Value

P/E: -1.5x
PEG: 0.0x
P/B: 4.2x

See GNG's fair value

BCDA Profitability: Margins, ROIC and FCF

Operating margin: 0.0%
Net margin: 0.0%
ROE: -1803.0%

BCDA Competitors

Company	Ticker
Heart Test Laboratories Inc. Common Stock	HSCS
Marker Therapeutics Inc	MRKR
Cyclerion Therapeutics Inc	CYCN
Tscan Therapeutics Inc	TCRX
Psyence Biomedical Ltd. Common Shares	PBM
IRIDEX Corporation	IRIX
Concord Medical Services Holdings	CCM
Dare Bioscience Inc	DARE

Sector: Healthcare

BCDA Bull Case vs Bear Case

Bull case

BCDA beat EPS estimates in 75.0% of its last 8 reported quarters.

Bear case

BCDA's quarterly revenue changed -100.0% year over year.

BCDA Earnings: Beat Rate and Next Report

Beat rate: 6 of 8 quarters (75.0%)
Average surprise: 21.3%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.15
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 1 up, 0 down

Frequently Asked Questions About BCDA

Does BCDA pay dividends?

Biocardia Inc (BCDA) does not currently pay a regular dividend.

What is BCDA's market cap?

Biocardia Inc (BCDA) has a market capitalization of $14.99M with a current stock price of $0.94.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In